Reply: Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD

JACC CardioOncol. 2024 Jun 25;6(4):627. doi: 10.1016/j.jaccao.2024.05.011. eCollection 2024 Aug.
No abstract available